On Biostatistics and Clinical Trials

CQ's web blog on the issues in biostatistics and clinical trials.

Tuesday, November 29, 2022

Randomized withdrawal design in action - Accord trial in Alzheimer's agitation

›
The biotech company, Axsome Therapeutics, announced the positive results from one of their pivotal phase 3 studies (Accord study).  Axsome...
2 comments:
Tuesday, November 15, 2022

Treatment Emergent AEs (TEAEs), On-Study AEs, On-Treatment AEs, Non-TEAEs

›
During the clinical trial, the adverse events (AEs) are collected from the signing of the informed consent to the last dose of the study dru...
Friday, November 11, 2022

Rolling Review, Real time oncology review (RTOR), and Split real time application review (STAR) Program

›
For New Drug Application (NDA) and Biological License Application (BLA), the usual process is to submit the entire package with different mo...
Thursday, October 20, 2022

Multiple Endpoints in Clinical Trials (Final) - FDA Guidance for Industry

›
Today, the FDA finalized its guidance for industry " Multiple Endpoints in Clinical Trials ". The draft version of this guidance w...
1 comment:
Sunday, October 16, 2022

Risk difference and confidence interval for Analyses of AEs and Clinical Laboratory Data

›
Several years ago, I posted an article " Should hypothesis tests be performed and p-values be provided for safety variables in efficacy...
Saturday, October 08, 2022

PDUFA, GDUFA, BSUFA, and MDUFA - FDA's User Fee Programs

›
For professionals who are working in drug development areas, the term PDUFA should be a very familiar term. As a matter of fact, FDA's a...
Monday, September 19, 2022

FMQ (FDA Medical Query) and SMQ (Standardized MedDRA Query)

›
For clinical trials, the safety analyses are mainly based on the analyses of the adverse events including serious adverse events. The advers...
Friday, September 02, 2022

Communicating with FDA: Type A, B, C, D meetings, and INTERACT meeting,

›
For any drug development program, the early and sometimes frequent communications are critical. However, the formal communications between t...
Monday, August 22, 2022

Story of BrainStorm's Stem Cell Treatment for ALS - Criticality of the Statistical Analyses

›
This past week, the biotech company BrainStorm announced the decision to submit a BLA to the FDA for NurOwn® (a stem cell treatment) for th...
Sunday, August 21, 2022

Mediation analysis and SAS CAUSALMED procedure

›
In a recent publication (Benza et al " Contemporary Risk Scores Predict Clinical Worsening in Pulmonary Arterial Hypertension - An Anal...
Thursday, August 18, 2022

Handling of values below or above a threshold (Below the Low Limit of Quantification or Above the Upper Limit of Quantification)?

›
In clinical trials, the samples are often collected and sent to the central laboratory or specialty laboratory for measuring certain paramet...
Monday, August 01, 2022

Placebo effect and its impact on the overall treatment effect

›
RCTs (randomized, controlled clinical trials) are still the golden standard in clinical research. In RCTs, the most common control group is ...
Friday, July 29, 2022

CRO, ARO, and VRO - All types of clinical research organizations

›
CRO (Contract Research Organization or Clinical Research Organization) A CRO is a company that provides clinical trial management services f...
2 comments:
Sunday, June 26, 2022

Adverse event / serious adverse event data entry when death event occurs

›
If the death event is an efficacy endpoint in the study, should the death event still be reported as AE/SAE?  If the death (or mortality) is...
‹
›
Home
View web version

About Me

My photo
Web blog from Dr. Deng
Chapel Hill, NC, United States
邓春勤 A Medical Doctor turned into Biostatistician in Clinical Trial and Drug Development Industry
View my complete profile
Powered by Blogger.